Elekta (OTCMKTS:EKTAY) Stock Jumps 5.5% – Should You Buy?

Elekta AB (OTCMKTS:EKTAY) was up 5.5% on Monday. The stock traded as high as $5.57 and last traded at $5.57. 100 shares changed hands during trading, a decline of 97% from the average daily volume of 2,869 shares. The stock had previously closed at $5.28.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Elekta Price Performance

The company’s fifty day moving average price is $5.38 and its 200-day moving average price is $5.49. The stock has a market cap of $2.05 billion, a P/E ratio of -46.41 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.62 and a current ratio of 0.86.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. The firm had revenue of $372.30 million during the quarter. Elekta had a negative net margin of 2.38% and a positive return on equity of 13.47%. Equities analysts forecast that Elekta AB will post 0.43 EPS for the current year.

About Elekta

Elekta AB is a Sweden-based medical technology company that develops and supplies systems and software for radiation therapy, radiosurgery and related cancer-care applications. Its solutions are designed to help hospitals and clinics treat tumors while supporting more precise, personalized and less invasive care.

The company’s portfolio includes linear accelerators, stereotactic radiosurgery systems, magnetic resonance-guided radiation therapy technology and brachytherapy products. Elekta also provides oncology information systems and workflow software, including platforms used for treatment planning, patient management and clinical data coordination.

Founded in 1972 by neurosurgeon and inventor Lars Leksell, Elekta initially focused on radiosurgery and later expanded into broader radiation oncology.